title: Delayed occurrence of H-ras12V-induced hepatocellular carcinoma with long-term treatment with cinnamaldehydes.
abstract: Cinnamaldehyde from the bark of Cinnamomum cassia has been reported to have antitumor activity mediated by the inhibition of farnesyl transferase. We assessed in vivo the chemo-preventive effect of cinnamaldehydes on H-ras12V-induced hepatocellular carcinoma formation. A mouse model of hepatocellular carcinoma was established by using the transgene of mutated H-ras12V under the regulation of albumin enhancer/promoter. When treated with cinnamaldehyde for 10 weeks, hepatic tumor development was delayed with 2'-benzoyloxycinnamaldehyde (BCA) compared with control hepatocellular carcinoma formation. The effect of 2'-hydroxycinnamaldehyde (HCA) was comparable. The number of lesions and the size of each lesion were significantly reduced by BCA. Cell proliferation in the lesion was detected by incorporation of 5-bromo-2'-deoxyuridine (BrdU). BCA increased the number of splenocytes, concanavalin A-stimulated splenocyte proliferation and the infiltration of lymphocytes into liver. Data suggest that the delayed hepatic tumor development observed with BCA could be mediated by a long-term immunostimulating effect on T cells.
authors.affiliation: Department of Human Genomics, Korea Research Institute of Bioscience and Biotechnology, 52 Oun-Dong, Yusong-Gu, Taejeon 305-806, Korea. eunyi@kribb.re.kr
authors.forename: Eun-Yi
authors.initials: EY
authors.lastname: Moon
authors.forename: Mi-Ran
authors.initials: MR
authors.lastname: Lee
authors.forename: Ai-Guo
authors.initials: AG
authors.lastname: Wang
authors.forename: Jun-Hee
authors.initials: JH
authors.lastname: Lee
authors.forename: Hyoung-Chin
authors.initials: HC
authors.lastname: Kim
authors.forename: Hwan-Mook
authors.initials: HM
authors.lastname: Kim
authors.forename: Jin-Man
authors.initials: JM
authors.lastname: Kim
authors.forename: Byoung-Mog
authors.initials: BM
authors.lastname: Kwon
authors.forename: Dae-Yeul
authors.initials: DY
authors.lastname: Yu
mesh_terms: D000171:Acrolein / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D001565:Benzoates / Q000494:pharmacology*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects; D005260:Female; D011905:Genes, ras / Q000235:genetics; D022781:Hepatocytes / Q000187:drug effects / Q000378:metabolism; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D041681:NIH 3T3 Cells; D013154:Spleen / Q000166:cytology; D047368:Tumor Burden / Q000187:drug effects
chemical_list: C484327:2'-benzoyloxycinnamaldehyde; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D001565:Benzoates; D000171:Acrolein; C012843:cinnamaldehyde